N

Navamedic ASA
OSE:NAVA

Watchlist Manager
Navamedic ASA
OSE:NAVA
Watchlist
Price: 21.8 NOK -0.46% Market Closed
Market Cap: 385m NOK
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one NAVA stock under the Base Case scenario is 66.25 NOK. Compared to the current market price of 21.8 NOK, Navamedic ASA is Undervalued by 67%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

NAVA Relative Value
Base Case
66.25 NOK
Undervaluation 67%
Relative Value
Price
N
Worst Case
Base Case
Best Case

Valuation Multiples

0.7
P/S
P/S
Price to Sales
0.7
vs History
96
vs Industry
76
Median 3Y
1.3
Median 5Y
1.4
Industry
2.4
Forward
0.7
More Details
298.5
P/E
P/E
Price to Earnings
298.5
vs History
11
vs Industry
0
Median 3Y
31.3
Median 5Y
21.4
Industry
21
Forward
29.5
More Details
10
P/OCF
P/OCF
Price to OCF
10
vs History
63
vs Industry
37
Median 3Y
33.5
Median 5Y
16.5
Industry
16.2
More Details
10
P/FCFE
P/FCFE
Price to FCFE
10
vs History
44
vs Industry
29
Median 3Y
11.8
Median 5Y
7.8
Industry
24
More Details
1.6
P/B
P/B
Price to Book Value
1.6
vs History
96
vs Industry
45
Median 3Y
2.9
Median 5Y
2.6
Industry
2
More Details
0.8
EV/S
EV/S
Enterprise Value to Sales
0.8
vs History
96
vs Industry
76
Median 3Y
1.4
Median 5Y
1.4
Industry
2.6
Forward
0.7
More Details
2
EV/GP
EV/GP
Enterprise Value to Gross Profit
2
vs History
96
vs Industry
70
Median 3Y
3.5
Median 5Y
3.7
Industry
5.1
More Details
13
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
13
vs History
60
vs Industry
27
Median 3Y
13.6
Median 5Y
13.6
Industry
12.6
Forward
7.6
More Details
13
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
13
vs History
63
vs Industry
32
Median 3Y
16.1
Median 5Y
14.5
Industry
16
Forward
9.6
More Details
10.7
EV/OCF
EV/OCF
Enterprise Value to OCF
10.7
vs History
63
vs Industry
36
Median 3Y
32.3
Median 5Y
16
Industry
14.4
More Details
10.7
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
10.7
vs History
49
vs Industry
30
Median 3Y
17
Median 5Y
10.5
Industry
17.6
More Details
1.1
EV/IC
EV/IC
Enterprise Value to IC
1.1
vs History
96
vs Industry
54
Median 3Y
1.7
Median 5Y
1.8
Industry
1.8
More Details

Multiples Across Competitors

NAVA Competitors Multiples
Navamedic ASA Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
NO
Navamedic ASA
OSE:NAVA
385m NOK 0.7 298.5 13 13
US
Eli Lilly and Co
NYSE:LLY
684.8B USD 14 61.7 33.2 36.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
369.5B USD 4.1 16.9 12.4 16.3
DK
Novo Nordisk A/S
CSE:NOVO B
2T DKK 6.6 19.2 13.3 15.3
CH
Roche Holding AG
SIX:ROG
207B CHF 3.4 25 9.4 11
CH
Novartis AG
SIX:NOVN
181.7B CHF 4.1 17.2 10.2 13.6
UK
AstraZeneca PLC
LSE:AZN
161.2B GBP 4 28 131.4 198.2
US
Merck & Co Inc
NYSE:MRK
192.2B USD 3 11 8.2 10
IE
Endo International PLC
LSE:0Y5F
163.5B USD 70.5 -56 261.3 655.3
US
Pfizer Inc
NYSE:PFE
133.3B USD 2.1 16.9 7.3 10.3
P/E Multiple
Earnings Growth PEG
NO
N
Navamedic ASA
OSE:NAVA
Average P/E: 54.9
298.5
270%
1.1
US
Eli Lilly and Co
NYSE:LLY
61.7
50%
1.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
16.9
27%
0.6
DK
Novo Nordisk A/S
CSE:NOVO B
19.2
18%
1.1
CH
Roche Holding AG
SIX:ROG
25
32%
0.8
CH
Novartis AG
SIX:NOVN
17.2
17%
1
UK
AstraZeneca PLC
LSE:AZN
28
36%
0.8
US
Merck & Co Inc
NYSE:MRK
11
17%
0.6
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -56 N/A N/A
US
Pfizer Inc
NYSE:PFE
16.9
30%
0.6
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
NO
N
Navamedic ASA
OSE:NAVA
Average EV/EBITDA: 395.1
13
42%
0.3
US
Eli Lilly and Co
NYSE:LLY
33.2
30%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
12.4
7%
1.8
DK
Novo Nordisk A/S
CSE:NOVO B
13.3
13%
1
CH
Roche Holding AG
SIX:ROG
9.4
5%
1.9
CH
Novartis AG
SIX:NOVN
10.2
5%
2
UK
AstraZeneca PLC
LSE:AZN
131.4
10%
13.1
US
Merck & Co Inc
NYSE:MRK
8.2
8%
1
IE
E
Endo International PLC
LSE:0Y5F
261.3
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.3
2%
3.7
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
NO
N
Navamedic ASA
OSE:NAVA
Average EV/EBIT: 1 698.3
13
41%
0.3
US
Eli Lilly and Co
NYSE:LLY
36.3
33%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
16.3
13%
1.3
DK
Novo Nordisk A/S
CSE:NOVO B
15.3
14%
1.1
CH
Roche Holding AG
SIX:ROG
11
6%
1.8
CH
Novartis AG
SIX:NOVN
13.6
10%
1.4
UK
AstraZeneca PLC
LSE:AZN
198.2
21%
9.4
US
Merck & Co Inc
NYSE:MRK
10
12%
0.8
IE
E
Endo International PLC
LSE:0Y5F
655.3
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.3
10%
1

See Also

Summary
NAVA intrinsic value, competitors valuation, and company profile.
DCF Valuation
NAVA stock valuation using Discount Cash Flow valuation method.
Relative Valuation
NAVA stock valuation using valuation multiples.
Wall Street Estimates
NAVA price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
NAVA stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 258,200+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.